Therapy Areas: Vaccines
Applied DNA partners with Evvivax for Phase I clinical trial of LinearDNA COVID-19 vaccine candidate in felines, with strong neutralizing antibody titer elicited across cohort
13 April 2021 -

DNA company Applied DNA Sciences Inc (NASDAQ:APDN) said on Monday that its Evvivax, S.R.L. programme development partner has announced positive preliminary Phase I clinical trial results for a LinearDNA COVID-19 vaccine candidate in adult domestic felines.

The companies added that the results follow administration of a single prime dose of the LinearDNA COVID-19 vaccine candidate on day one in late February indicate that the LinearDNA vaccine candidate is well-tolerated by the cohort.

In addition, a SARS-CoV-2 neutralization assay was conducted by the Cornell University Animal Health Diagnostic Center at the College of Veterinary Medicine 20 days after prime dose delivery to establish the immune response of all cohort members. The results of the neutralization assay yielded high titers of SARS-CoV-2 neutralizing antibodies (NAb) from all cohort members.

Concurrently, the follow-on NAb assay results upon administration of LinearDNA COVID-19 vaccine candidate booster are expected in late April 2021. The companies intend to extend the evaluation of neutralizing antibodies in select cohort members through September 2021.

Under the Phase I is a single-centre clinical trial, the companies evaluated domestic feline immune response, safety and tolerability of the vaccine candidate with a cohort of 11 healthy, client-owned domestic felines and conducted at GVS. The LinearDNA vaccine candidate is administered intramuscularly via gene electrotransfer of primer and booster 28-35 days apart.

Assuming the Phase I endpoint is met, the companies plan to initiate Phase II that will involve the placement of seroconverted vaccinated non-client-owned cats among infected cats, with the primary endpoint being the percent of vaccinated cats that resist infection.